What Happened

Pasithea Therapeutics announced interim Phase 1 data showing PAS-004, their macrocyclic oral MEK inhibitor, demonstrated favorable safety with only Grade 1/2 adverse events and no cardiac/retinal toxicity. The protocol was amended to escalate dosing up to 52mg and initiate a food effect study to optimize chronic dosing strategies.

Who Is Affected

Oncology biotechs developing MEK inhibitors or combination therapies for RAS/RAF/NF1-mutated cancers are directly impacted. Academic medical centers running clinical trials for NF1 and MAPK pathway tumors should track this development. Patients who failed prior BRAF/MEK inhibitor treatments showed stable disease >6 months on PAS-004.

Market Impact

• Creates pressure on MEK inhibitor developers to demonstrate comparable long-term tolerability
• Validates macrocyclic approach for chronic dosing in oncology
• Potential to shift treatment paradigms for BRAF/MEK inhibitor-resistant patients

What to Watch

Key milestones include MTD determination from extended dose escalation (18-52mg) and food effect study results. Phase 1/1b data in NF1 patients (NCT06961565) will further validate PAS-004's chronic dosing potential. Competitors may accelerate development of next-gen MEK inhibitors.